Madrigal Q2 Revenue Jumps 71% to $364M as Rezdiffra Patient Count Tops 49,000
MDGL sits 86% above its 52-week low of $286.44.
Summary
Madrigal's Q2 revenue surged 71% year-over-year to $364.25 million, driven by strong Rezdiffra demand with over 49,000 patients on therapy. The net loss widened to $57.94 million as operating expenses climbed to $420.56 million, reflecting heavy commercial investment and R&D. This follows Q1's 127% revenue growth and recent pipeline advances, including a Phase 1 start for MGL-2086 and new patents. The revenue beat and rapid patient adoption reinforce the launch trajectory, though rising costs and lack of guidance keep the outlook mixed. With a $659.50 median price target, the market will watch for margin improvement and further pipeline updates.
At the time of this announcement, MDGL was trading at $533.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $286.44 to $615.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.